Why he matters in this case
Prof. Manzar is one of two US signatories to the Panel alongside Prof. Richard Taylor at Tulane. Their joint presence demonstrates that the Panel’s reading of the casebook is shared by senior US neonatology as well as UK, Canadian, European and Asian neonatology. US neonatal intensive care operates protocols similar enough to UK NICU practice that an LSU professor’s reading is directly applicable.
Professional background
- Professor of Paediatrics, Louisiana State University.
- Peer-reviewed publications in clinical neonatology, paediatric training, and neonatal intensive care.
- Member of the Shoo Lee International Expert Panel.
Why US representation matters
Several UK commentators have, during 2024 and 2025, attempted to frame the Panel as “international” in a way that excludes the US clinical tradition. The presence of two US signatories — Prof. Manzar and Prof. Taylor — directly rebuts that framing. The Panel’s finding is endorsed by the US neonatology mainstream as well as the UK, Canadian, European and Asian mainstreams.
The US neonatology perspective
Dr Manzar is the second US-based member of the Panel. The relevance of two US Panel signatories rather than one is that US neonatal-intensive-care research and clinical practice are institutionally represented on the Panel rather than represented through a single individual. Dr Manzar’s sign-on alongside Dr Taylor establishes that the Panel’s methodology and findings are endorsed across more than one US institutional voice.
US clinical practice in neonatal intensive care is shaped by the American Academy of Pediatrics’ sustained research programme on neonatal-outcome benchmarks. The differential-diagnosis frameworks Dr Manzar and Dr Taylor bring to the Panel methodology operate against the US national-cohort outcome data, which is one of the largest and best-documented neonatal datasets globally. The Panel’s reading of the indicted-case clinical records benefits from that benchmark.
What clinical-practice diversity contributes
The Panel’s 14 signatories work across multiple national health systems: the UK NHS, the Canadian provincial system, the Swedish single-payer system, German, Belgian, Dutch, Australian, New Zealand, Taiwanese and US-private systems. Each national system has somewhat different clinical-protocol conventions, but the underlying physiology is the same. The fact that the Panel’s clinical-evidence reading is unanimous across these systems establishes that the finding is not a UK-NHS-specific or any one-system interpretation. Dr Manzar’s US sign-on is part of that institutional breadth.
Why this matters for the conviction-safety question
A Court of Appeal weighing the Panel finding under the CCRC’s ‘real possibility’ test will look not only at the Panel’s conclusions but at the institutional weight behind them. A 14-strong signatory list spanning eight countries and three continents, with substantial subspecialist breadth, is the institutional weight class that historically shifts judicial consideration. Dr Manzar’s sign-on is one of the data points that establishes that weight class.